MESO Mesoblast limited.

$MESO it’s been one year of b.s. sideways trading despite excellent execution imho we are WAY overdue for a run !!! Let’s go!!!

$MESO $MESO bull case is getting much easier to quantify: • RYONCIL generated $115.2M FY26 net revenue in its first full launch year • $103.6M gross profit on $120.3M total revenue • Net loss fell 44%; 2H operating cash burn was only $13.4M • More than 50 transplant centers onboarded, including 14 of the 15 largest pediatric sites • Coverage now exceeds 280M lives • Median time from patient identification to treatment improved from 29 days to 8 days • Adult aGvHD registrational trial is enrolling; management says that market is 3× larger than pediatrics • The 350-patient Phase 3 chronic low-back-pain trial is fully treated, with topline data expected mid-2027 • FDA just approved a new commercial RYONCIL potency assay, strengthening manufacturing consistency and scalability This is no longer a pre-revenue cell-therapy story: it now has a commercial product funding multiple late-stage expansion opportunities.

$MESO: Mesoblast (+3.3%) receives FDA approval to use a new potency assay for commercial Ryoncil lot release and stability monitoring.

$MESO Keep an eye on MESO as each day is closer to the Ryoncil quarterly sales update, which the company has been releasing about the 10th of the month after quarter end. If sales have kept on their trend of increasing quarter over quarter, they are going to be very close to putting up a cash flow positive quarter!